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Diploid human fibroblast strains were treated for 10 min with inhibitors of type I and type II DNA
topoisomerases, and after removal of the inhibitors, the rate of initiation of DNA synthesis at replicon origins
was determined. By alkaline elution chromatography, 4'-(9-acridinylamino)methanesulfon-m-anisidide (amsa-
crine), an inhibitor of DNA topoisomerase II, was shown to produce DNA strand breaks. These strand breaks
are thought to reflect drug-induced stabilization of topoisomerase-DNA cleavable complexes. Removal of the
drug led to a rapid resealing of the strand breaks by dissociation of the complexes. Velocity sedimentation
analysis was used to quantify the effects of amsacrine treatment on DNA replication. It was demonstrated that
transient exposure to low concentrations of amsacrine inhibited replicon initiation but did not substantially
affect DNA chain elongation within operating replicons. Maximal inhibition of replicon initiation occurred 20
to 30 min after drug treatment, and the initiation rate recovered 30 to 90 min later. Ataxia telangiectasia cells
displayed normal levels of amsacrine-induced DNA strand breaks during stabilization of cleavable complexes
but failed to downregulate replicon initiation after exposure to the topoisomerase inhibitor. Thus, inhibition of
replicon initiation in response to DNA damage appears to be an active process which requires a gene product
which is defective or missing in ataia telangiectasia cells. In normal human fibroblasts, the inhibition of DNA
topoisomerase I by camptothecin produced reversible DNA strand breaks. Transient exposure to this drug also
inhibited replicon initiation. These results suggest that the cellular response pathway which downregulates
replicon initiation following genotoxic damage may respond to perturbations of chromatin structure which
accompany stabilization of topoisomerase-DNA cleavable complexes.
DNA topoisomerases are a class of nuclear enzymes
which are capable of forming covalent complexes with
DNA. Formation of these complexes involves scission of the
phosphodiester backbone of DNA, with covalent linkage of
the topoisomerase to one end of the cutting site (6, 13, 40).
The other cut end apparently remains associated with the
topoisomerase. These complexes of topoisomerase associ-
ated with cut or cleaved DNA are known as cleavable
complexes. For type I topoisomerases from mammalian
cells, a single DNA break is produced in the complex, and
free rotation of the cut strand about the intact strand allows
relaxation of supercoiled molecules. Type II topoisomerases
produce closely opposed cuts in the two strands of duplex
DNA, allowing passage of strands through the DNA duplex.
The formation of topoisomerase-DNA complexes which
allow relaxation of supercoiled DNA or passage of double
strands of DNA may facilitate transcription of RNA and
replication of DNA (3, 5, 9). Both type I and type II
topoisomerases have been shown to play roles in replication
of the simian virus 40 (SV40) circular replicon in a cell-free
system (37, 42). Topoisomerase I was found to contribute to
chain elongation, presumably by relieving supercoiling ten-
sion in front of advancing replication forks. This function
could be replaced by topoisomerase II. Topoisomerase II
was also required for the final stages of separation of the
topologically intertwined sister duplexes. This result was
consistent with demonstrations that temperature-sensitive
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topoisomerase II yeast mutants were arrested in G2 when
incubated at the restrictive temperature (7). Recent results
also implicate topoisomerases as endogenous suppressors of
homologous recombination (41). The vital nature of these
enzyme activities is exemplified by the demonstration that
they are the targets for a variety of cytotoxic drugs used
clinically to treat certain cancers (34, 39). Many of these
drugs stabilize the topoisomerase-DNA cleavable complex,
and the resulting DNA strand breaks can be discerned with
a strong protein denaturant. Topoisomerase inhibitors pro-
duce dramatic cytogenetic damage, including sister chroma-
tid exchange and chromosome aberrations (17). Thus, the
mechanism of drug action is of interest for the rational design
of drug therapy regimens.
To date, there have been few studies of the mechanisms of
inhibition of DNA replication by drugs which interfere with
topoisomerase activity. Flow cytometric analysis had re-
vealed a delayed progression of human leukemic cells
through S phase during incubation with etoposide [4'-deme-
thylepipodophyllotoxin-9-(4,6-O-ethylidene-p-D-glucopyra-
noside)], an inhibitor of type II topoisomerase (16). Inhibi-
tion of DNA synthesis was postulated to be the result of an
effect on replicon initiation. Inhibition of DNA and RNA
synthesis has also been observed in cells treated with
camptothecin, an inhibitor of type I topoisomerase (12).
In this study, we have used alkaline elution chromatogra-
phy to quantify the numbers of topoisomerase-DNA com-
plexes that are formed during exposure of human cells to
inhibitors of type I and type II topoisomerases. Velocity
sedimentation analysis was used to quantify drug-induced
effects on replicon initiation and DNA chain elongation. The
results suggest that the biological damage to DNA induced
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by stabilizing topoisomerase-DNA complexes triggers a
stereotypic adaptive response pathway that produces a rapid
downregulation of the replicon initiation rate. Disregulation
of this pathway may have profound pathologic conse-
quences, as exemplified by the enhanced frequencies of
DNA metabolic errors in ataxia telangiectasia (AT) cells (1,
8, 23, 35).
MATERIALS AND METHODS
Human cell strains and cell culture conditions. Diploid
human fibroblasts were derived from foreskin in this labora-
tory (NHF-1) or obtained from the Human Genetic Mutant
Cell Respository (a normal strain, GM3348, and an AT
strain, AT4BE [GM3487B]) and the American Type Culture
Collection (xeroderma pigmentosum [XP] strain XP4BE
[CRL1162]). An SV40-transformed XP line (GM4429B) and
a large-T-antigen transformed AT line (GM9607) were ob-
tained from the Human Genetic Mutant Cell Repository. The
SV80 fibroblast line (SV40 transformed) was provided by
Betsy Sutherland, Brookhaven National Laboratory. Nor-
mal and AT lymphoblastoid cell lines were provided by
Michael Swift, University of North Carolina at Chapel Hill.
Diploid and transformed fibroblasts were grown as described
previously (19). Lymphoblasts were grown in RPMI 1640
medium supplemented with 2 mM L-glutamine, 20% fetal
bovine serum, 200 ,ug of kanamycin per ml, and 50 jig of
gentamicin per ml. Prior to drug treatment and analysis of
strand breakage or DNA replication, cells were grown for at
least two generations in medium containing [14C]thymidine
(50 Ci/mol; 5 to 20 nCi/ml). Cells were then incubated in
isotope-free medium for at least 4 h before experimental
treatments.
Drug treatment. Camptothecin and amsacrine were sup-
plied by the Natural Products Branch, Division of Cancer
Treatment, National Cancer Institute. For cells growing on
plastic dishes, drugs were added in dimethyl sulfoxide (final
concentration of solvent was 0.5%). After 10 min of incuba-
tion at 37°C, the medium was removed, the cells were rinsed
twice with warm Hanks balanced salt solution, and fresh
growth medium was added. For suspension cultures of
lymphoblasts, cells were sedimented out of drug-containing
medium and then resuspended in fresh drug-free medium.
Alkaline elution chromatography. For determination of
DNA breakage by alkaline elution, monolayer cell cultures
were harvested by scraping into ice-cold phosphate-buffered
saline. Suspension cultures were sedimented and resus-
pended in the same buffer. Cells were deposited on polycar-
bonate filters, lysed, and washed with alkaline elution buffer
as described previously (21). We found that addition of
proteinase K to the lysis solution had no effect on DNA
elution from the polycarbonate filters, and therefore protein-
ase treatment during lysis was not included. The initial rate
of elution of DNA during washing with alkaline buffer was
quantified from the release of 14C radioactivity from filters
and converted to a frequency ofDNA strand breaks accord-
ing to a calibration curve (21).
Velocity sedimentation analysis. Analysis of DNA replica-
tion in drug-treated cells was done as previously described
(4, 19). Briefly, following drug treatment, [14C]thymidine-
labeled cells were incubated for 10 or 15 min with [3H]thy-
midine (10 to 50 ,uCi/ml; 56 Ci/mmol). Cells were harvested
by scraping or by sedimentation and lysed on top of 5 to 20%
alkaline sucrose gradients. After sedimentation at 25,000
rpm for 4 h, the gradients were fractionated, and acid-
insoluble radioactivity was quantified. Within an experiment
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FIG. 1. Inhibition of DNA synthesis and fragmentation of paren-
tal DNA in amsacrine-treated fibroblasts. XP variant fibroblasts
(XP4BE) were treated with 100 or 300 ,uM amsacrine for 30 min and
then pulsed with [3H]thymidine for 10 min in drug-free medium.
Cells were harvested, and DNA strand sizes were evaluated by
velocity sedimentation in alkaline sucrose gradients. (A) Normal-
ized 3H cpm represent the acid-insoluble 3H radioactivity in each
gradient fraction divided by the total acid-insoluble 14C radioactivity
in the gradient. Profiles therefore depict the rates of synthesis of
DNA in various size classes of nascent intermediates normalized to
constant cell number. Total 3H cpm in these gradients were 2,422,
864, and 424 for solvent-treated controls (solid circles), 100 ,uM
amsacrine-treated cells (open squares), and 300 F.M amsacrine-
treated cells (solid triangles), respectively. (B) Profiles of ['4C]thy-
midine-labeled parental DNA. Total 14C cpm were 1,300 to 1,800
cpm. Symbols are as in panel A. Sedimentation was from right to
left. Approximate DNA molecular weights are indicated by vertical
arrows. DMSO, dimethyl sulfoxide.
with replicate cell cultures, the level of incorporation of
[14C]thymidine was used as an estimate of cell numbers. The
[3H]Thymidine that was incorporated during a 10- to 15-min
pulse was normalized to the cell number. The steady-state
distribution of nascent DNA molecules, which was revealed
by the profile of 3H radioactivity (19), was therefore also a
representation of DNA synthesis activity in replicons at
various levels of maturation (31). In practice, we looked for
drug-induced changes in the incorporation of [3H]thymidine
into replication intermediates that had initiated synthesis
before the drug treatment (which reveals rates of chain
elongation in operating replicons) and into replicons that
initiated synthesis after the drug treatment (which reveals
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FIG. 2. DNA strand breaks in amsacrine-treated human fibro-
blasts. Confluent cultures of NHF-1 cells were treated with various
concentrations of amsacrine for 10 min and either harvested imme-
diately for alkaline elution analysis (A) or incubated in drug-free
medium for various intervals after removal of amsacrine (B). The
low background number of strand breaks in solvent-treated controls
(<2 per 1010 Da) has been subtracted. Error bars depict 1 standard
deviation about the mean (n = 3).
rates of replicon initiation). Calibration of the gradients with
size standards had been done previously (19).
Cell synchronization. Diploid human fibroblasts were ar-
rested in Go by growth to confluence followed by 3 days of
incubation in medium containing 0.5% serum. Proliferating
cells were synchronized to G1 by first arresting them at
confluence and then replating at lower cell density into fresh
medium. After 7 h, the cells were in G1. Addition of
aphidicolin at 6 ,uM after arrested cells were replated caused
up to 80% of the cells to accumulate at the beginning of the
S phase (21). Removal of the aphidicolin after 24 h released
these cells into the S phase. Cells were sampled 3 h after
removal of aphidicolin, when in the middle of S, or 7 h after
removal of aphidicolin, when in G2. Cells collected in the
various cell cycle phases (GO, G1, S, and G2) were incubated
with 2 ,uM amsacrine for 10 min before determination of
DNA strand breaks by alkaline elution.
RESULTS
A pilot experiment was done first with high concentrations
of amsacrine. XP variant fibroblasts (4) were incubated for
30 min with 100 or 300 p.M amsacrine, and immediately after
removal of the drug, rates ofDNA synthesis were quantified
after a 10-min pulse with [3H]thymidine. Cells were lysed on
top of alkaline sucrose gradients, and nascent (3H-labeled)
and parental (14C-labeled) DNA strands were separated
according to size by velocity sedimentation. [3H]Thymidine
incorporation into acid-insoluble DNA was normalized to
cell number, which allows quantification of the synthesis of
nascent DNA molecules at various stages of processing (19,
31). Drug treatment severely inhibited DNA replication, as
reflected in the reduced incorporation of precursor into all
size classes of nascent DNA (Fig. 1A). These concentrations
of drug also produced breaks in parental DNA (Fig. 1B).
Subsequent studies were done in which cells were incu-
bated with lower concentrations of amsacrine for 10 min and
DNA fragmentation was quantified by alkaline elution. This
technique relies upon the fact that DNA strand breaks
facilitate the unwinding of DNA in alkali and increase the
initial rate of release of DNA from polycarbonate filters.
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FIG. 3. Concentration-dependent inhibition of DNA replication
by amsacrine. Diploid fibroblast strains, both XP variants (A) and
normals (B), were treated with various concentrations of amsacrine
for 10 min and then incubated in drug-free medium for 30 min. Cells
were incubated with [3H]thymidine for 15 min and then harvested
for velocity sedimentation analysis. (A) XP variant fibroblasts:
circles, solvent (DMSO)-treated control; squares, 1.0 p.M amsa-
crine; triangles, 10 F.M amsacrine. Total "4C, 1,600 to 2,900 cpm;
total 3H, 4,300 to 5,000 cpm. (B) Normal human fibroblasts. Solid
circles, solvent (DMSO)-treated control; open circles, 0.1 ,uM
amsacrine; squares, 1.0 ,uM amsacrine; triangles, 10 FM amsacrine.
Total 14C, 570 to 620 cpm; total 3H, 5,000 to 9,000 cpm. The
increments of normalized 3H cpm are 0.025 and 0.25 cpm, respec-
tively, in panels A and B.
These filters do not bind protein well, especially after cells
are lysed in sodium dodecyl sulfate (22, 25), and treatment of
cell lysates with proteinase K before adding alkali had no
effect on DNA elution (results not shown). Concentrations
of amsacrine in the range of 0.05 to 1 p.M produced a
dose-dependent increase in the frequency of DNA strand
breaks (Fig. 2A). A plateau in the response was seen after a
higher concentration, suggesting saturation. The maximal
frequency of DNA strand breaks was 3 breaks per 109 Da.
When medium containing amsacrine was removed from cell
cultures, reversal of strand breakage occurred (Fig. 2B). By
30 min after removal of 1 ,uM amsacrine, the frequency of
DNA strand breaks was equivalent to those seen in un-
VOL. 11, 1991
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FIG. 4. Inhibition of replicon initiation by amsacrine. Diploid
fibroblasts (NHF-1) were treated with DM80 or 1 ,uM amsacrine for
10 min and then washed free of drug. Cells were incubated with
[3H]thymidine for 15 mm, beginning immediately or 20, 60, or 120
min after addition of drug-free medium. Total 14C, 1,800 to 2,000
cpm; total 3H, 2,500 to 6,000 cpm. Increments of normalized 3H cpm
are 0.05 cpm.
treated controls. For the purposes of this presentation, it will
be assumed that the DNA strand breaks induced by topo-
isomerase inhibitors reflect the presence of stabilized topo-
isomerase-DNA cleavable complexes.
To examine the effect on DNA replication of brief inhibi-
tion of topoisomerase II activity, we first examined two
strains of human fibroblasts which had previously been
distinguished in the laboratory (4) by their capacity for
postreplication repair after exposure to carcinogens. XP
variant and normal diploid human fibroblast strains were
treated with various concentrations of amsacrine and then
incubated for 30 min in drug-free medium before DNA
replication was assayed by velocity sedimentation. Exposing
the normal fibroblast strain GM3348 to 0.1 ,uM amsacrine
modestly inhibited incorporation of precursor into molecules
of about 20 MDa and smaller (fractions 17 to 20) without
noticeably affecting DNA synthesis in larger intermediates
(Fig. 3B). The average replicon size in diploid human fibro-
blasts is 20 ,Lm, and a single-stranded DNA molecule of 20
MDa has a mass one-half that of an average replicon. After
exposure to 1 ,uM amsacrine, DNA synthesis in such half-
replicon-size intermediates (20 MDa) was inhibited by about
50%, while synthesis in multireplicon-size intermediates
(fractions 5 to 13) remained near control rates. This selective
inhibition of DNA synthesis in half-replicon-size intermedi-
ates is characteristic of inhibition of replicon initiation (19,
20, 29-32). A higher concentration of drug (10 ,uM) reduced
synthesis in multireplicon-size intermediates by about 30 to
70%, suggesting that residual levels of the drug also inhibited
chain elongation within operating replicons (19, 20). An
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FIG. 5. Amsacrine-induced DNA strand breaks in AT cells.
Human cell strains or lines were treated with various concentrations
of amsacrine for 10 min and harvested immediately (solid symbols)
or after 30 min of incubation in drug-free medium (open symbols).
(A) Circles, AT4BE, diploid AT fibroblasts; squares, GM9607,
T-antigen-transformed AT fibroblasts; triangles, 590 AT, lympho-
blastoid AT cells. (B) Circles, SV80, SV40-transformed normal
human fibroblasts; squares, GM4429B, SV40-transformed XP fibro-
blasts; triangles, 599N, normal lymphoblastoid cells.
the XP variant fibroblast strain (Fig. 3A), which had previ-
ously been shown to be defective in a pathway of postrepli-
cation repair after UV irradiation (4). The XP variant cells
did not appear to be hypersensitive to treatment with the
topoisomerase inhibitor.
To determine the generality of the response in normal
human fibroblasts and to further characterize its features,
time course studies were done with another diploid strain,
NHF-1, that had been treated with the low concentration (1
,uM) of amsacrine (Fig. 4). Immediately after removal of the
drug, there was little change in sedimentation profiles,
although the reduction in radioactivity in fractions 17 to 20 is
consistent with early phases of inhibition of replicon initia-
tion. By 20 min after removal of drug, the effect on replicon
initiation was more fully exposed. The point at which the
profile for treated cells diverged from that for the control had
moved from fraction 17 at time zero (10 min of drug
exposure) to fraction 14 by 20 min after removal of the drug.
By 60 min after removal of the drug, the point of divergence
had moved to fraction 11. At this time, DNA synthesis in
half-replicon-size intermediates (fractions 17 to 20) had
begun to recover, and by 2 h after removal of the amsacrine,
rates of initiation of DNA synthesis had recovered to near
control levels. This pattern of inhibition of DNA synthesis
sweeping with time from low-molecular-weight intermedi-
ates to higher-molecular-weight nascent molecules is identi-
cal to the pattern of cellular response to DNA damage
produced by low doses of UV light, ionizing radiation, and
benzo[a]pyrene diolepoxide I (19, 20, 31). Experiments
similar to these done with etoposide, a nonintercalative
inhibitor of type II topoisomerase, revealed the same pattern
of response (18).
AT cells display radioresistant DNA synthesis, in which
the pathway for downregulation of replicon initiation ap-
pears to be defective (30, 32). It had been reported that AT
cells may express reduced levels of topoisomerase 11 (26).
To test for a possible deficit in topoisomerase II activity in
.0I 20' l
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FIG. 6. Amsacrine resistant replicon initiation in AT cells. The cell strains or lines described in the legend to Fig. 5 were treated with 1
,uM amsacrine (open circles), 3 ,uM amsacrine (open triangles, panel D) or DMSO (solid circles) for 10 min, and after 30 min of incubation
in fresh drug-free medium, the cells were pulsed for 15 min with [3H]thymidine. Rates ofDNA synthesis in various size classes of replication
intermediates were determined by velocity sedimentation analysis. (A) NHF-1; (B) 599N; (C) SV80; (D) AT4BE; (E) 590AT; (F) GM9607.
The net 3H cpm in gradient fractions are depicted, as the total 14C cpm in paired gradients were equal.
AT cells, various AT cells were treated with amsacrine, and
then DNA strand breakage and replicon initiation were
quantified. In each of the AT cell cultures, exposure to
amsacrine produced DNA strand breaks which were re-
versed upon removal of drug (Fig. 5A). This transient
exposure to amsacrine had, however, no effect on DNA
replication in the diploid, lymphoblast, and large-T-antigen-
transformed AT cells (Fig. 6D, E, and F). Amsacrine was
also shown to produce reversible DNA strand breaks in
SV40-transformed normal and XP fibroblast lines and a
normal lymphoblastoid line (Fig. 5B). The normal lympho-
blastoid line and the SV40-transformed normal fibroblast line
responded to the amsacrine as did the normal diploid fibro-
blasts, with inhibition of replicon initiation (Figure 6A, B,
and C). The inhibition of chain elongation in active replicons
seen in some of the amsacrine-treated cells (Fig. 6B and C)
probably reflects the presence of residual drug.
The diploid AT strain appeared to express fewer topoisom-
erase-associated strand breaks than the transformed AT
cells and the normal diploid fibroblast strain (Fig. 2 and 5A).
This was considered to reflect a lower growth fraction in the
diploid AT strain, with topoisomerase II levels being related
to cell proliferation activity. To test for cell proliferation-
dependent regulation of topoisomerase II, the diploid fore-
skin fibroblast strain NHF-1 was arrested in Go or synchro-
nized to the G1, S, or G2 phase of the cell cycle (21), and
levels of amsacrine-induced DNA strand breaks were quan-
tified by alkaline elution. Go and G1 cells expressed about
60% as many DNA strand breaks as S and G2 cells (results
not shown). All analyses of topoisomerase-dependent DNA
strand breakage in diploid cells (Fig. 2, 5, and 7) were done
with cells arrested in Go by growth to confluence followed by
3 days of incubation in 0.5% serum. Consequently, the levels
of stabilized topoisomerase-DNA complexes in diploid cells
presented in Fig. 2 and 5 probably underestimate the number
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FIG. 7. Camptothecin-induced DNA strand breaks. The NHF-1
fibroblast strain was incubated with various concentrations of camp-
tothecin for 10 min and either harvested immediately (solid symbols)
or incubated for an additional 30 min in drug-free medium (open
symbols). DNA strand breaks were determined by alkaline elution
analysis. The dashed line depicts the average number of strand
breaks seen in solvent-treated controls. The solid line was calcu-
lated by linear regression of the logarithm of camptothecin concen-
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FIG. 8. Inhibition of DNA replication by camptothecin. (A)
NHF-1 fibroblasts were incubated with camptothecin for 25 min and
with [3H]thymidine for the last 15 min of drug exposure. (B)
Replicate cultures were treated with camptothecin for 10 min and
then incubated in drug-free medium for 30 min before being pulsed
with [3H]thymidine for 15 min. Rates of DNA synthesis in various
size classes of replication intermediates were determined by veloc-
ity sedimentation analysis. Solid circles, solvent-treated control;
open circles, 0.03 ,uM camptothecin; solid triangles, 0.3 puM camp-
tothecin. Total "'C was 3,000 cpm in this experiment.
Analyses of DNA strand breaks in amsacrine-treated trans-
formed cells were done with cells in log-phase growth, in
which all cell cycle phases are represented.
Given the stereotypic pattern of response to inhibition of
topoisomerase II, an inhibitor of topoisomerase I was stud-
ied to see whether the response pathway recognized the
stabilization of a different cleavable complex. Camptothecin
was shown to produce DNA strand breaks which were fully
reversed within 30 min after removal of the drug (Fig. 7).
During continuous exposure to camptothecin, DNA replica-
tion was inhibited in multireplicon-size intermediates, sug-
gesting that the cleavable complexes interfere with DNA
chain elongation (Fig. 8A). However, when the drug was
removed, this inhibition was reversed and the inhibition of
replicon initiation became evident. Some residual effect on
DNA synthesis in multireplicon-size intermediates was seen
after removal of camptothecin, but this was not concentra-
tion dependent. Indeed, very low levels of drug-induced
damage to DNA appeared to be sufficient to inhibit replicon
initiation. A maximal effect was seen after exposure to 0.03
,uM camptothecin, which induced only about 3 DNA breaks
per 1010 Da.
DISCUSSION
Transient freezing of topoisomerase-DNA cleavable com-
plexes was demonstrated to activate a stereotypic response
pathway involving selective downregulation of the rate of
replicon initiation. This response was seen following expo-
sure to inhibitors of topoisomerase II (amsacrine and etop-
oside [18]) and topoisomerase I (camptothecin) in normal
human fibroblasts. This response pathway was also demon-
strated in normal human lymphoblasts, transformed fibro-
blasts, and diploid XP variant fibroblasts after inhibition of
topoisomerase II with amsacrine. The inhibition of replicon
initiation was not seen in two AT cell lines or a diploid AT
strain after treatment with amsacrine. This implies that the
radioresistant DNA synthesis which characterizes the AT
phenotype is expressed at the level of a generalized adaptive
response pathway triggered by perturbation of chromatin
DNA structure. AT cells are also defective in downregula-
tion of replicon initiation after UV and ionizing radiation
treatment (30, 32). In comparison to normal cells and AT
heterozygotes, AT homozygotes may express approximately
10-fold-higher frequencies of radiation-induced chromatid-
type chromosomal aberrations (8). AT cells were reported to
be hypersensitive to killing by etoposide (11, 36), consistent
with a model that inhibition of replicon initiation protects
against genotoxic damage (29).
The mechanisms of action of the topoisomerases have
been extensively investigated, as have the effects of the
topoisomerase inhibitors (6, 13, 40). Amsacrine intercalates
into the DNA duplex, whereas etoposide has weak DNA-
binding activity. Both drugs stabilize the topoisomerase
II-DNA cleavable complex. The levels of drug-induced
DNA strand breaks identified in these studies are quite
similar to those identified previously in diploid human fibro-
blast strains (44, 45), and the AT cells were confirmed to
express normal levels of amsacrine-dependent DNA break-
age (45). Levels of amsacrine-dependent DNA strand breaks
were moderately affected by proliferative status in the fore-
skin fibroblast strain, with quiescent Go cells exhibiting 60%
as many strand breaks as S-phase and G2-phase proliferating
cells. This modest variation in amsacrine-dependent strand
breaks between quiescent and proliferating cells is in good
agreement with results reported by Zwelling et al. (44), who
used very similar assay conditions. The observation that the
cellular levels of topoisomerase II, as determined by immu-
noblotting, may vary in diploid human fibroblast strains by
as much as 20-fold between quiescence and active growth
(15) suggests that the amsacrine-induced DNA strand breaks
which are seen by alkaline elution analysis reflect the activ-
ity of only a small fraction of the cellular topoisomerase II.
Although topoisomerases appear to provide a swivel ac-
tion to relieve topological strain or supercoiling tension and
to separate intertwined daughter chromatids, stabilization of
the topoisomerase II-DNA cleavable complex with amsa-
crine does not appear to allow relaxation of nucleoid struc-
tures (33). Consequently, even though the phosphodiester
bond is cut and only one cut end of DNA is covalently linked
to protein, the other cut end appears to be held by the
protein in a way which retains or preserves chromatin
topological structure. In spite of this apparent lack of alter-
ation in chromatin supercoiling tension during stabilization
of the cleavable complex, human cells recognize some
alteration associated with a brief exposure to the inhibitor
and activate the pathway of downregulation of the replicon
initiation rate. It appears at first glance to be paradoxical that
the rate of replicon initiation would be reduced by inhibiting
the separation of intertwined daughter chromatids with the
topoisomerase II inhibitors. We had previously suggested
that by stabilizing the topoisomerase-DNA complex, the
replication complex would remain occupied and would not
be available for initiating replication within replicon clusters
(18). This direct steric effect does not appear to be the case
because, according to such a model, the AT cells should
display inhibition of replicon initiation, which they do not.
Intercalation also does not appear to be necessary to trigger
the response, because the nonintercalative inhibitor etopo-
side is active (18). Consequently, we now suggest that
critical DNA damage is produced when DNA replication
occurs in the vicinity of topoisomerase-DNA complexes,
and it is this damage which activates downregulation of
replicon initiation. AT cells are unable to activate this
response pathway owing to their underlying genetic defect.
It has been proposed that progression of DNA replication
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forks into cleavable complexes may produce lethal cellular
damage (14). Denaturation of duplex strands at the sites of
cleavable complexes could produce irreversible DNA dou-
ble-strand breaks, which lead to lethal chromatid aberrations
(2, 18). Because topoisomerases appear to be required for
replication and may be integral components of the replica-
tion complex (27), such a mechanism of drug-induced ge-
netic damage would be very efficient. The observation that
essentially continuous exposure to camptothecin and amsa-
crine inhibited DNA chain elongation in operating replicons
is consistent with a model that drug-stabilized cleavable
complexes represent a block to fork progression (Fig. 1A
and 8A).
Cells have evolved a variety of mechanisms for repairing
DNA damage. The downregulation of replicon initiation rate
provides more time for repairing damage before DNA repli-
cation and so should interact synergistically with DNA
repair pathways to reduce the risk of S-phase-dependent
mutations and chromatid aberrations (18, 29). The response
pathway of inhibition of replicon initiation appears to share
regulatory elements with a pathway which produces G2
arrest. Both pathways are susceptible to inhibition by caf-
feine (i.e., caffeine prevents the down regulation of replicon
initiation rate [29] and reduces the length of G2 arrest [38]).
Diploid AT fibroblasts also demonstrate radiation-resistant
replicon initiation (32) and reduced G2 delay following
irradiation (43). Evidently, the pathways of downregulation
of replicon initiation and G2 delay normally provide more
time for repair of potentially lethal (23) and potentially
clastogenic (8, 28) cellular damage. It is notable in this regard
that treatment of Chinese hamster ovary cells with etoposide
or X irradiation has been shown to produce a rapid inhibition
of p34cdc2 kinase activity, which was proposed as the mech-
anism of G2 delay (24). Thus, it appears that the biochemical
pathways which induce cell cycle delays after genomic
damage also share components with the pathways which
normally regulate cell growth and division (10).
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